Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MDMA to establish ethics code

This article was originally published in The Gray Sheet

Executive Summary

Medical Device Manufacturers Association is developing a code-of-conduct similar to those for PhRMA and AdvaMed, MDMA Chairman Chris Chavez, CEO of Advanced Neuromodulation Systems, reports at a Morgan Stanley healthcare conference in Miami. The National Electrical Manufacturers Association's code of ethics was approved at the end of 2004; AdvaMed's has been in effect for two years (1"The Gray Sheet" Dec. 6, 2004, p. 12)...

You may also be interested in...



NEMA Code Clarifies Ethics Of R&D Grants, Drops “Entertainment” Entirely

The National Electrical Manufacturers Association's new code of ethics endorses strict parameters for device company allocation of research funds to healthcare providers

Can Synthetic CBD Overcome Cannabis Stigma And Break EU Novel Foods Deadlock?

Czech firm CBDepot has filed a novel food application for synthetically made CBD in Europe, which it hopes regulators will find more palatable than those for supplements derived from the cannabis plant.

Regulatory Blessings Helping China CAR-Ts March Closer To Global Cancer Patients?

A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.

UsernamePublicRestriction

Register

MT022074

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel